alzamend neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of alzheimer’s disease, bipolar disorder, major depressive disorder (“mdd”) and post-traumatic stress disorder (“ptsd”). our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ million americans suffering from these debilitating diseases. our current pipeline consists of two novel therapeutic drug candidates, al001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and alzn002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat alzheimer’s.